167 related articles for article (PubMed ID: 36193036)
1. Respiratory characteristics in children with spinal muscular atrophy type 1 receiving nusinersen.
Xiao L; Chiang J; Castro-Codesal M; Kolski H; Bedi P; Al Amrani F; Gonorazky HD; Amin R;
Pediatr Pulmonol; 2023 Jan; 58(1):161-170. PubMed ID: 36193036
[TBL] [Abstract][Full Text] [Related]
2. Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience.
Lavie M; Diamant N; Cahal M; Sadot E; Be'er M; Fattal-Valevski A; Sagi L; Domany KA; Amirav I
Pediatr Pulmonol; 2021 Jan; 56(1):291-298. PubMed ID: 33111497
[TBL] [Abstract][Full Text] [Related]
3. Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen.
Ergenekon AP; Yilmaz Yegit C; Cenk M; Gokdemir Y; Erdem Eralp E; Ozturk G; Unver O; Kenis Coskun O; Karadag Saygi E; Turkdogan D; Karadag B
Pediatr Int; 2022 Jan; 64(1):e15175. PubMed ID: 35522792
[TBL] [Abstract][Full Text] [Related]
4. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
[TBL] [Abstract][Full Text] [Related]
5. Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen.
Menard J; Seferian AM; Fleurence E; Barzic A; Binoche A; Labouret G; Coutier L; Vuillerot C; Bieleu BM; Gomez Garcia de la Banda M; Corvol H; Servais L; Taytard J
Pediatr Pulmonol; 2022 Jun; 57(6):1505-1512. PubMed ID: 35307979
[TBL] [Abstract][Full Text] [Related]
6. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen.
de Holanda Mendonça R; Jorge Polido G; Ciro M; Jorge Fontoura Solla D; Conti Reed U; Zanoteli E
J Neuromuscul Dis; 2021; 8(2):217-224. PubMed ID: 33459657
[TBL] [Abstract][Full Text] [Related]
9. Sleep disordered breathing in infants identified through newborn screening with spinal muscular atrophy.
Chiang J; Xiao L; Nigro E; St-Laurent A; Weinstock L; Law E; Janevski J; Kuyntjes S; Cithiravel N; Tran T; Wolter NE; Gonorazky H; Amin R;
Sleep Med; 2023 Nov; 111():161-169. PubMed ID: 37778092
[TBL] [Abstract][Full Text] [Related]
10. A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results.
Jiang Y; Wang Y; Xiong H; Li W; Luo R; Chen W; Yin F; Lü J; Liang J; Chen WJ; Lu X; Wang H; Tang J; Monine M; Makepeace C; Jin X; Foster R; Chin R; Berger Z
Adv Ther; 2024 Jul; 41(7):2743-2756. PubMed ID: 38722537
[TBL] [Abstract][Full Text] [Related]
11. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study.
Crawford TO; Swoboda KJ; De Vivo DC; Bertini E; Hwu WL; Finkel RS; Kirschner J; Kuntz NL; Nazario AN; Parsons JA; Pechmann A; Ryan MM; Butterfield RJ; Topaloglu H; Ben-Omran T; Sansone VA; Jong YJ; Shu F; Zhu C; Raynaud S; Lago TR; Paradis AD; Foster R; Chin R; Berger Z;
Muscle Nerve; 2023 Aug; 68(2):157-170. PubMed ID: 37409780
[TBL] [Abstract][Full Text] [Related]
12. Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience.
Gonski K; Chuang S; Teng A; Thambipillay G; Farrar MA; Menezes MP; Fitzgerald DA
Neuromuscul Disord; 2023 Jun; 33(6):531-538. PubMed ID: 37290230
[TBL] [Abstract][Full Text] [Related]
13. Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen.
Sansone VA; Pirola A; Albamonte E; Pane M; Lizio A; D'Amico A; Catteruccia M; Cutrera R; Bruno C; Pedemonte M; Messina S; Rao F; Roma E; Salmin F; Coratti G; Di Bari A; De Sanctis R; Pera CM; Sframeli M; Piastra M; Macagno F; Vita G; Bertini E; Mercuri E
J Pediatr; 2020 Apr; 219():223-228.e4. PubMed ID: 32035635
[TBL] [Abstract][Full Text] [Related]
14. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study.
Aragon-Gawinska K; Seferian AM; Daron A; Gargaun E; Vuillerot C; Cances C; Ropars J; Chouchane M; Cuppen I; Hughes I; Illingworth M; Marini-Bettolo C; Rambaud J; Taytard J; Annoussamy M; Scoto M; Gidaro T; Servais L
Neurology; 2018 Oct; 91(14):e1312-e1318. PubMed ID: 30158155
[TBL] [Abstract][Full Text] [Related]
15. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
[TBL] [Abstract][Full Text] [Related]
16. Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients.
Lavie M; Rochman M; Sagi L; Yerushalmy Feler A; Ovadia D; Cahal M; Be'er M; Sadot E; Fattal-Valevski A; Amirav I
Pediatr Pulmonol; 2022 Mar; 57(3):686-694. PubMed ID: 34921596
[TBL] [Abstract][Full Text] [Related]
17. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
[TBL] [Abstract][Full Text] [Related]
18. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen.
Weststrate H; Stimpson G; Thomas L; Scoto M; Johnson E; Stewart A; Muntoni F; Baranello G; Conway E;
Dev Med Child Neurol; 2022 Jul; 64(7):907-914. PubMed ID: 35103306
[TBL] [Abstract][Full Text] [Related]
19. Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec.
Leon-Astudillo C; Wagner M; Salabarria SM; Lammers J; Berthy J; Zingariello CD; Byrne BJ; Smith BK
Sleep Med; 2023 Jan; 101():234-237. PubMed ID: 36442421
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
[No Abstract] [Full Text] [Related]
[Next] [New Search]
